688506 Stock Overview
Engages in the research and development, production, and marketing of small molecule chemical, macromolecular biological, and antibody-drug conjugate drugs in China and internationally. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sichuan Biokin Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥203.09 |
52 Week High | CN¥238.80 |
52 Week Low | CN¥106.03 |
Beta | 0 |
11 Month Change | 7.90% |
3 Month Change | 19.65% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 71.15% |
Recent News & Updates
Recent updates
Shareholder Returns
688506 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 12.0% | 0.3% | -0.6% |
1Y | n/a | -7.9% | 3.2% |
Return vs Industry: Insufficient data to determine how 688506 performed against the CN Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 688506 performed against the CN Market.
Price Volatility
688506 volatility | |
---|---|
688506 Average Weekly Movement | 10.1% |
Pharmaceuticals Industry Average Movement | 7.4% |
Market Average Movement | 8.4% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688506 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688506's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 2,264 | Yi Zhu | www.baili-pharm.com |
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and marketing of small molecule chemical, macromolecular biological, and antibody-drug conjugate drugs in China and internationally. Sichuan Biokin Pharmaceutical Co.,Ltd.
Sichuan Biokin Pharmaceutical Co.,Ltd. Fundamentals Summary
688506 fundamental statistics | |
---|---|
Market cap | CN¥81.44b |
Earnings (TTM) | CN¥3.80b |
Revenue (TTM) | CN¥5.85b |
21.4x
P/E Ratio13.9x
P/S RatioIs 688506 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688506 income statement (TTM) | |
---|---|
Revenue | CN¥5.85b |
Cost of Revenue | CN¥272.85m |
Gross Profit | CN¥5.57b |
Other Expenses | CN¥1.77b |
Earnings | CN¥3.80b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 9.48 |
Gross Margin | 95.33% |
Net Profit Margin | 64.99% |
Debt/Equity Ratio | 36.2% |
How did 688506 perform over the long term?
See historical performance and comparison